BiotechTube

PLX-200 + Placebo

Phase 3Recruiting
0 watching 0 views this week📈 Rising
69
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Juvenile Neuronal Ceroid Lipofuscinosis

Conditions

Juvenile Neuronal Ceroid Lipofuscinosis

Trial Timeline

Mar 1, 2026 → Mar 31, 2026

NCT ID
NCT04637282

About PLX-200 + Placebo

PLX-200 + Placebo is a phase 3 stage product being developed by Polaryx Therapeutics for Juvenile Neuronal Ceroid Lipofuscinosis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04637282. Target conditions include Juvenile Neuronal Ceroid Lipofuscinosis.

Hype Score Breakdown

Clinical
27
Activity
18
Company
2
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT04637282Phase 3Recruiting

Competing Products

20 competing products in Juvenile Neuronal Ceroid Lipofuscinosis

See all competitors
ProductCompanyStageHype Score
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
77
MRA(Tocilizumab) + placeboChugai PharmaceuticalPhase 3
77
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
77
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
77
AdalimumabEisaiPhase 3
77
AbataceptOno PharmaceuticalPhase 3
77
Ixekizumab + AdalimumabEli LillyPhase 3
77
Baricitinib + PlaceboEli LillyPhase 3
77
BaricitinibEli LillyPhase 3
77
Baricitinib + TocilizumabEli LillyPhase 3
77
adalimumab + MethotrexateAbbViePre-clinical
23
UpadacitinibAbbViePhase 1
33
Upadacitinib + TocilizumabAbbViePhase 3
77
Adalimumab + RisankizumabAbbViePhase 3
77
AdalimumabAbbViePhase 3
77
naproxen + esomeprazoleAstraZenecaPhase 1
33
Alendronate (Fosamax)MerckPre-clinical
23
canakinumabNovartisPhase 3
77
SecukinumabNovartisPhase 1
33
ACZ885 150 mg (Canakinumab)NovartisPhase 3
77